Mark A. Varney
Fondateur chez Neurolixis, Inc.
Profil
Mark A.
Varney is the founder of Neurolixis, Inc. Prior to founding Neurolixis, he held several positions in the pharmaceutical industry, including President, CEO & Director at RespireRx Pharmaceuticals, Inc., Director-San Diego Facility at Merck & Co., Inc., Director-Neuropharmacology at Sibia Neurosciences, Inc., Vice President & Head-Discovery at Sumitomo Pharma America, Inc., and Vice President-Drug Discovery at Bionomics Ltd.
Varney holds a doctorate from the University of Oxford and an undergraduate degree from the University of Surrey.
Postes actifs de Mark A. Varney
| Sociétés | Poste | Début |
|---|---|---|
Neurolixis, Inc.
 Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Fondateur | - |
Anciens postes connus de Mark A. Varney
| Sociétés | Poste | Fin |
|---|---|---|
| RESPIRERX PHARMACEUTICALS INC. | President | 22/03/2013 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/01/2006 |
| BIONOMICS LIMITED | Corporate Officer/Principal | 01/06/2004 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/04/2003 |
| Sibia Neurosciences, Inc. | Corporate Officer/Principal | 01/09/1999 |
Formation de Mark A. Varney
| University of Oxford | Doctorate Degree |
| University of Surrey | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| BIONOMICS LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
| Sibia Neurosciences, Inc. | Health Technology |
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |